PNT Stock Price, POINT Biopharma Global . Quote, Chart

Market Summary

USD73.98+0.38

Market Closed

0.52%

PNT Stock Price

View Fullscreen

PNT RSI Chart

PNT Valuation

Market Cap

7.8B

Price/Earnings (Trailing)

83.09

Price/Sales (Trailing)

34.81

EV/EBITDA

53.59

Price/Free Cashflow

86.51

PNT Price/Sales (Trailing)

PNT Profitability

EBT Margin

56.10%

Return on Equity

22.76%

Return on Assets

20.21%

Free Cashflow Yield

1.16%

PNT Fundamentals

PNT Revenue

Revenue (TTM)

226.6M

Rev. Growth (Qtr)

-42.66%

PNT Earnings

Earnings (TTM)

96.6M

Earnings Growth (Yr)

-3.17%

Earnings Growth (Qtr)

2.5%

Breaking Down PNT Revenue

Last 7 days

-3.2%

Last 30 days

-4.7%

Last 90 days

10.9%

Trailing 12 Months

54.2%

How does PNT drawdown profile look like?

PNT Financial Health

Current Ratio

9.14

PNT Investor Care

Shares Dilution (1Y)

0.88%

Diluted EPS (TTM)

1.1

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	0
2022	0	0	0	226.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of POINT Biopharma Global Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 27, 2023	lubner david charles	back to issuer	-	-	-3,600	-
Dec 27, 2023	margolin yael	back to issuer	-	-	-1,710	-
Dec 26, 2023	hogue gerald l.	sold	-	-	-21,596	-
Dec 26, 2023	lubner david charles	sold	-	-	-35,400	-
Dec 26, 2023	malik rajesh	sold	-	-	-3,700	-
Dec 26, 2023	goodman jonathan r.	sold	-	-	-41,872	-
Dec 22, 2023	fleshner neil e.	sold	-	-	-2,773,040	chief medical officer
Dec 22, 2023	silber allan c	sold	-	-	-38,087	executive chairman
Dec 22, 2023	silber allan c	sold	-	-	-4,035,660	executive chairman
Dec 22, 2023	silber allan c	sold	-	-	-4,268,600	executive chairman

Which funds bought or sold PNT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 22, 2024	MetLife Investment Management, LLC	sold off	-100	-309,415	-	-%
Mar 11, 2024	VANGUARD GROUP INC	sold off	-100	-31,134,100	-	-%
Mar 05, 2024	Fisher Asset Management, LLC	sold off	-100	-661,590	-	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	sold off	-100	-1,614,610	-	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	sold off	-100	-301,204	-	-%
Feb 16, 2024	GSA CAPITAL PARTNERS LLP	sold off	-100	-93,000	-	-%
Feb 16, 2024	PRICE T ROWE ASSOCIATES INC /MD/	sold off	-100	-244,000	-	-%
Feb 15, 2024	BARCLAYS PLC	sold off	-100	-949,000	-	-%
Feb 15, 2024	JANE STREET GROUP, LLC	sold off	-100	-190,082	-	-%
Feb 15, 2024	State of Wyoming	sold off	-100	-28,054	-	-%

Are Funds Buying or Selling PNT?

Are funds buying PNT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PNT

No. of Funds

Unveiling POINT Biopharma Global Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Dec 27, 2023	silber allan c	0%	0	SC 13D/A
Dec 20, 2023	biotechnology value fund l p	-	0	SC 13D/A
Nov 06, 2023	biotechnology value fund l p	8.5%	8,974,245	SC 13D
Oct 03, 2023	silber allan c	8.8%	9,316,184	SC 13D/A
Feb 14, 2023	biotechnology value fund l p	4.7%	4,916,306	SC 13G/A
Feb 03, 2023	blackrock inc.	5.1%	5,393,438	SC 13G
Nov 22, 2022	silber allan c	8.74%	9,231,368	SC 13D/A
Sep 26, 2022	ra capital management, l.p.	0%	0	SC 13D/A
Sep 26, 2022	biotechnology value fund l p	2.9%	2,991,213	SC 13G
Sep 16, 2022	ra capital management, l.p.	8.65%	9,003,018	SC 13D/A

Peers (Alternatives to POINT Biopharma Global Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.9B	6.8B	-0.89%	-25.81%	-8.47	5.83	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.4B	1.8B	-0.46%	-30.31%	-41.72	10.05	76.23%	61.08%
BMRN	16.9B	2.4B	5.17%	-8.18%	100.76	6.98	15.42%	18.43%
INCY	11.7B	3.7B	-8.90%	-30.41%	19.5	3.15	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-13.99%	-44.77%	-10.87	14.48	425.83%	18.94%
BBIO	4.4B	-	-15.28%	57.81%	-6.75	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-11.84%	-2.48%	-14.08	12.45	440.80%	-27.84%
ARWR	3.0B	240.7M	-11.98%	-22.42%	-9.98	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.29%	-15.38%	-45.68	3.85	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-3.94%	-8.31%	24.94	4.47	85.90%	-14.05%
NVAX	572.4M	983.7M	-12.98%	-52.88%	-1.05	0.58	-50.36%	17.16%
CRBP	395.6M	881.7K	7.90%	326.47%	-8.87	466.16	-77.61%	-5.33%
INO	233.7M	4.9M	-13.94%	-3.10%	-1.73	48.02	-54.97%	51.71%
IBIO	6.2M	2.1M	63.30%	36.92%	-0.23	2.14	-13.45%	66.37%

POINT Biopharma Global Inc. News

Latest updates

POINT Biopharma Global Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In null)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4
Revenue	-42.7%	3.00	5.00	9.00	-
Operating Expenses	-10.9%	32.00	36.00	32.00	35.00
S&GA Expenses	8.2%	6.00	5.00	5.00	7.00
R&D Expenses	-14.0%	27.00	31.00	27.00	28.00
EBITDA Margin	3.4%	0.66*	0.64*	0.62*	0.60*
Interest Expenses	5.3%	6.00	5.00	6.00	3.00
Income Taxes	194.6%	1.00	-0.92	-0.24	31.00
Earnings Before Taxes	9.2%	-23.90	-26.33	-16.77	194
EBT Margin	-0.1%	0.56*	0.56*	0.57*	0.57*
Net Income	2.5%	-24.77	-25.41	-16.53	163
Net Income Margin	-0.8%	0.43*	0.43*	0.43*	0.43*
Free Cashflow	57.7%	-34.53	-81.67	-25.92	235

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet															(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Assets	-4.0%	478	498	559	578	326	234	253	263	277	297	136	22.00	137	-	-
Current Assets	-18.3%	353	432	435	531	296	205	233	244	259	282	1.00	12.00	1.00	0.00	0.00
Cash Equivalents	-62.3%	22.00	57.00	111	286	126	78.00	227	239	253	274	20.00	11.00	19.00	7.00	-
Net PPE	-	-	-	35.00	31.00	29.00	24.00	20.00	19.00	18.00	16.00	-	10.00	-	-	-
Liabilities	6.3%	54.00	50.00	87.00	91.00	17.00	19.00	14.00	8.00	8.00	12.00	6.00	9.00	5.00	-	-
Current Liabilities	-6.0%	39.00	41.00	78.00	80.00	17.00	19.00	14.00	8.00	8.00	12.00	6.00	5.00	0.00	1.00	0.00
Shareholder's Equity	-5.2%	424	447	472	487	309	215	239	255	269	285	29.00	13.00	19.00	8.00	-
Retained Earnings	-844.7%	-27.71	-2.93	22.00	39.00	-124	-100	-75.67	-59.28	-45.09	-27.97	-1.71	-13.38	-0.18	-0.02	-0.01
Additional Paid-In Capital	0.4%	453	451	450	448	434	316	315	314	314	313	7.00	27.00	5.00	0.00	-
Shares Outstanding	0%	106	106	106	106	91.00	90.00	90.00	90.00	68.00	90.00	57.00	55.00	54.00	23.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Cashflow From Operations	62.2%	-28,132	-74,335	-22,391	236,916	-22,328	-20,578	-10,490	-11,527	-13,726	-8,477	-10,966	-4,517	-241	-18.01	-405	-
Share Based Compensation	9.7%	1,876	1,710	1,009	999	1,079	1,028	440	371	348	1,106	477	142	404	555	660	-
Cashflow From Investing	-136.2%	-7,401	20,437	-153,043	-89,727	-46,894	-128,702	-940	-2,482	-3,077	-3,055	-186	-	-70,895	-	-	-
Cashflow From Financing	-390.6%	-152	52.00	146	13,456	116,898	3.00	942*	-	-4,106	265,427	20,450	-	24,260	83.00	4,305	-

PNT Income Statement

2023-09-30

Unaudited Interim Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue
Revenue	$ 2,789,993	$ 0	$ 17,113,113	$ 0
Operating expenses
Research and development	26,910,286	20,797,406	85,097,331	54,112,136
General and administrative	5,505,869	3,839,626	15,604,401	11,727,969
Total operating expenses	32,416,155	24,637,032	100,701,732	65,840,105
Loss from operations	(29,626,162)	(24,637,032)	(83,588,619)	(65,840,105)
Other income (expenses)
Investment income	5,617,736	1,048,254	16,717,703	1,605,927
Foreign currency gain (loss)	105,522	(243,791)	(133,438)	(287,691)
Total other income (expenses)	5,723,258	804,463	16,584,265	1,318,236
Loss before income taxes	(23,902,904)	(23,832,569)	(67,004,354)	(64,521,869)
Income tax (provision) benefit	(871,449)	(180,500)	288,491	(452,021)
Net loss	$ (24,774,353)	$ (24,013,069)	$ (66,715,863)	$ (64,973,890)
Net loss per basic and diluted common share:
Basic net loss per common share (in dollars per share)	$ (0.23)	$ (0.26)	$ (0.63)	$ (0.71)
Diluted net loss per common share (in dollars per share)	$ (0.23)	$ (0.26)	$ (0.63)	$ (0.71)
Basic weighted average common shares outstanding (in shares)	105,765,954	92,401,484	105,717,330	90,891,031
Diluted weighted average common shares outstanding (in shares)	105,765,954	92,401,484	105,717,330	90,891,031

PNT Balance Sheet

2023-09-30

Interim Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 21,607,412	$ 286,428,371
Short-term investments	317,555,936	238,783,470
Prepaid expenses and other current assets	9,901,729	5,610,889
Income taxes receivable	4,181,469	0
Total current assets	353,246,546	530,822,730
Non-current assets
Long-term investments	59,793,161	16,119,430
Note receivable	5,116,667	0
Property, plant and equipment, net	54,042,353	31,380,576
Operating lease right-of-use asset	5,505,693	0
Total non-current assets	124,457,874	47,500,006
Total assets	477,704,420	578,322,736
Current liabilities
Accounts payable	8,886,750	7,703,150
Accrued liabilities	14,529,354	19,094,454
Deferred revenue	12,586,443	23,242,290
Income taxes payable	736,729	29,698,546
Finance lease current liability	987,018	0
Operating lease current liability	939,983	0
Total current liabilities	38,666,277	79,738,440
Deferred revenue, net of current portion	3,720,881	10,178,147
Long-term income taxes payable	2,389,109	1,452,356
Finance lease liability, net of current portion	4,093,202	0
Operating lease liability, net of current portion	4,642,565	0
Total liabilities	53,512,034	91,368,943
Commitments and contingencies (Note 12)
Stockholders’ equity
Common Stock, par value $0.0001 per share, 430,000,000 authorized, 105,765,954 and 105,649,741 issued and outstanding as of September 30, 2023 and December 31, 2022, respectively	10,576	10,565
Additional paid-in capital	453,319,762	448,391,574
(Accumulated deficit) Retained earnings	(27,707,358)	39,008,505
Accumulated other comprehensive loss	(1,430,594)	(456,851)
Total stockholders’ equity	424,192,386	486,953,793
Total liabilities and stockholders’ equity	$ 477,704,420	$ 578,322,736

About POINT Biopharma Global Inc.

POINT Biopharma Global Inc., a radiopharmaceutical company, develops and commercializes radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-alpha inhibitor targeting program being developed for use in various tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.

CEO	Dr. Joe A. McCann Ph.D.
WEBSITE	pointbiopharma.com
INDUSTRY	Biotechnology
EMPLOYEES	129

POINT Biopharma Global Inc. Frequently Asked Questions

What is the ticker symbol for POINT Biopharma Global Inc.? What does PNT stand for in stocks?

PNT is the stock ticker symbol of POINT Biopharma Global Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of POINT Biopharma Global Inc. (PNT)?

As of Mon Apr 22 2024, market cap of POINT Biopharma Global Inc. is 7.84 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PNT stock?

You can check PNT's fair value in chart for subscribers.

What is the fair value of PNT stock?

You can check PNT's fair value in chart for subscribers. The fair value of POINT Biopharma Global Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of POINT Biopharma Global Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PNT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is POINT Biopharma Global Inc. a good stock to buy?

The fair value guage provides a quick view whether PNT is over valued or under valued. Whether POINT Biopharma Global Inc. is cheap or expensive depends on the assumptions which impact POINT Biopharma Global Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PNT.

What is POINT Biopharma Global Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 22 2024, PNT's PE ratio (Price to Earnings) is 83.09 and Price to Sales (PS) ratio is 34.81. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PNT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on POINT Biopharma Global Inc.'s stock?

In the past 10 years, POINT Biopharma Global Inc. has provided 0.033 (multiply by 100 for percentage) rate of return.